September 14, 2021 -- ThermoGenesis has received a $250,000 Small Business Innovation Research (SBIR) phase I grant from the U.S. National Institutes of Health (NIH) to develop and test the company's single-use sterile cell-processing disposable product.
There are two specific aims of the NIH's grant, according to ThermoGenesis. The first aim is to prototype and manufacture in small quantities an enhanced X-Series cartridge. The second aim is to validate and optimize the performance of all steps of gene-engineered autologous cell therapy (GEAC) manufacturing in a single cartridge.
The company said it intends to apply for a phase II SBIR grant to design and validate the Quintessence instrument that will fully automate the specific workflow.